Physician profile
Mohammed Saad
NPI 1063854586
$8,204.89
in general payments reported to CMS, 2019-2025
47 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $1,063 · 2021: $2,127 · 2022: $2,712 · 2023: $524 · 2024: $857 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.35 |
| Education | $337.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,007.67 | 2019-2024 | Erleada, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $735.67 | 2020-2025 | Enhertu, Lynparza, Calquence |
| Pfizer INC. | $508.25 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $459.33 | 2019-2025 | |
| Incyte Corporation | $443.10 | 2019-2023 | Jakafi |
| Lilly USA, LLC | $407.26 | 2020-2024 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $308.38 | 2019-2022 | |
| Amgen INC. | $302.51 | 2019-2023 | Lumakras, Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $298.88 | 2019-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $284.49 | 2019-2023 | Opdivo |
| Eisai INC. | $283.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $282.38 | 2019-2025 | Jemperli, Ojjaara |
| Astellas Pharma US INC | $282.26 | 2019-2022 | |
| Genzyme Corporation | $247.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $230.20 | 2019-2025 | Keytruda, Lynparza |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.